前列腺健康指数密度在前列腺MRI意义不明确时诊断临床显著前列腺癌优于前列腺特异性抗原密度:一项多中心评估
这项多中心评估纳入10个泌尿中心1215例接受MRI引导靶向和系统穿刺的男性,比较前列腺健康指数、前列腺健康指数密度和PSA密度对临床显著前列腺癌的预测价值。结果显示,PI-RADS联合前列腺健康指数密度的AUC为0.85,优于PI-RADS联合PSA密度的0.81;在PI-RADS 3病变中,前列腺健康指数密度可减少72%的不必要穿刺。
要点
- 在PI-RADS 3病变中,前列腺健康指数密度减少72%的不必要穿刺,优于PSA密度的58%和前列腺健康指数的67%。
- 全队列中,PI-RADS联合前列腺健康指数密度的AUC为0.85,优于PI-RADS联合PSA密度(0.81)和PI-RADS(0.76)。
- 多变量分析中,前列腺健康指数(OR 1.04)、前列腺体积(OR 0.97)和PI-RADS 5(OR 8.34)是临床显著前列腺癌的独立预测因素。
核心结论
- 在接受多参数MRI的男性中,前列腺健康指数密度在检测临床显著前列腺癌方面优于前列腺健康指数或PSA密度,并在PI-RADS 3病变中进一步减少不必要的前列腺穿刺。
研究设计与样本
- 这是一项对10个泌尿中心前瞻性维护的前列腺穿刺数据库的多中心评估。
- 纳入同时具有前列腺健康指数和MRI引导靶向及系统前列腺穿刺、且无既往前列腺癌诊断的男性。
- 共分析1215例男性。
主要发现
- 前列腺癌和临床显著前列腺癌分别诊断于51%(617/1215)和35%(422/1215)的男性。
- 最高PI-RADS评分为2、3、4、5的病变中,临床显著前列腺癌诊断率分别为4.4%(3/68)、15%(72/470)、39%(176/446)和74%(171/231)。
- 多变量分析中,临床显著前列腺癌检测的独立预测因素包括前列腺健康指数(OR 1.04)、前列腺体积(OR 0.97)、PI-RADS评分4(OR 2.81)和5(OR 8.34)。
- 全队列中,临床显著前列腺癌的AUC:PI-RADS联合前列腺健康指数密度为0.85,优于PI-RADS联合PSA密度(0.81)、前列腺健康指数密度(0.81)、前列腺健康指数(0.78)、PI-RADS(0.76)、PSA密度(0.72)和PSA(0.60);在PI-RADS 3病变中也观察到前列腺健康指数密度的优越性。
- 决策曲线分析显示,在PI-RADS 3或4病例中,前列腺健康指数密度获得最佳净临床获益;在PI-RADS 3病变中,使用PSA密度0.15、前列腺健康指数38.0和前列腺健康指数密度0.83的截断值,分别可减少58%、67%和72%的不必要穿刺。
关键数值与推荐
- 在PI-RADS 3病变中,PSA密度0.15、前列腺健康指数38.0和前列腺健康指数密度0.83的截断值分别减少58%、67%和72%的不必要穿刺。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy. MATERIALS AND METHODS: This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy performed and without prior prostate cancer diagnosis were included. The additional value of PSA density, Prostate Health Index, and Prostate Health Index density to MRI PI-RADS (Prostate Imaging Reporting & Data System) score was evaluated with multivariable analyses, area under the curve, and decision curve analyses. The proportion of unnecessary biopsies that can be avoided are estimated for clinically significant prostate cancer (International Society of Urological Pathology group ≥2 prostate cancer). RESULTS: A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prostate cancer was diagnosed in 4.4% (3/68), 15% (72/470), 39% (176/446), and 74% (171/231) of highest PI-RADS score of 2, 3, 4, and 5 lesions, respectively. In multivariable analyses, independent predictors for clinically significant prostate cancer detection included Prostate Health Index (OR 1.04), prostate volume (OR 0.97), and PI-RADS score 4 (OR 2.81) and 5 (OR 8.34). Area under the curve for clinically significant prostate cancer of PI-RADS + Prostate Health Index density (0.85) was superior to PI-RADS + PSA density (0.81), Prostate Health Index density (0.81), Prostate Health Index (0.78), PI-RADS (0.76), PSA density (0.72), and PSA (0.60) in the whole cohort, and the superiority of Prostate Health Index density was also observed in PI-RADS 3 lesions. Decision curve analysis showed Prostate Health Index density achieving the best net clinical benefit in PI-RADS 3 or 4 cases. Among PI-RADS 3 lesions, using cutoffs of PSA density 0.15, Prostate Health Index 38.0, and Prostate Health Index density 0.83 could reduce 58%, 67%, and 72% of unnecessary biopsies, respectively. CONCLUSIONS: Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnecessary biopsies in PI-RADS 3 lesions.
引用
- Chiu PK, Leow JJ, Chiang CH, et al. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation. J Urol. 2023. PMID: 37036248. doi:10.1097/JU.0000000000003450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。